Monitor the upcoming corporate strategy webcast on September 10, 2026, for details on ROBBIN trial execution and potential updates on the BATTMAN termination fallout. The stock's reaction will depend on investor sentiment regarding the trade-off between the promising ROBBIN opportunity and the loss of the BATTMAN data readout.
Price Chart
Executive Summary
Agenus reported Q2 2026 total revenue of $34.5M (up 34% YoY from $25.7M), driven by $6.4M in pre-commercial BOT+BAL product revenue and $28.1M in non-cash royalty revenue. The company highlighted its oversubscribed $85M private placement to fund the Phase 3 ROBBIN trial, but also disclosed the termination of the BATTMAN Phase 3 study due to funding prioritization. The filing is neutral as the revenue beat is largely non-cash royalty revenue, and the strategic pivot to ROBBIN comes at the cost of the BATTMAN trial, creating offsetting signals for a pre-revenue biotech.
Key Financial Metrics
Key Facts
- Total revenue for Q2 2026 was $34.5M, up from $25.7M in Q2 2025.
- Pre-commercial BOT+BAL product revenue was $6.4M in Q2 2026, up from $4.6M in Q1 2026.
- Non-cash royalty revenue was $28.1M in Q2 2026, up from $24.8M in Q2 2025.
- Agenus completed an oversubscribed $85M private placement in July 2026 to support the ROBBIN trial.
- Agenus discontinued funding for the Phase 3 BATTMAN trial, leading to its termination by CCTG.
- Cash and cash equivalents were $35.0M as of March 31, 2026, with an additional $11.7M in net proceeds from ATM sales received post-quarter-end.
- The company expects the upfront proceeds from the private placement to support operations through Q3 2027.
Financial Impact
Revenue of $34.5M in Q2 2026, with $28.1M being non-cash royalty revenue. The $85M private placement provides a cash runway through Q3 2027.
Risk Factors
- Termination of the BATTMAN Phase 3 trial removes a key pipeline catalyst and may raise questions about clinical strategy.
- Reliance on non-cash royalty revenue for the majority of reported revenue does not provide actual cash flow.
- Execution risk for the large, global Phase 3 ROBBIN trial, which is still in the initiation phase.
- Potential shareholder dilution from the exercise of milestone-aligned warrants, which could provide up to $255M in additional proceeds.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-336780 |
| Document: agen-ex99_1.htm | 0001193125-26-336780 |
| Document: 0001193125-26-336780-index-headers.html | 0001193125-26-336780 |
| Document: 0001193125-26-336780-index.html | 0001193125-26-336780 |
| Document: 0001193125-26-336780.txt | 0001193125-26-336780 |
| 8-K Data (Synthetic) | 0001193125-26-336780 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | 8-K | $7.00 $6.94 | ▼ −0.86% | ▲ +0.89% | $8.32 (+18.86%) |
Aug 12, 2026 7w ago | Institutional Cluster | $6.90 $6.89 | ▼ −0.14% | ▲ +1.75% | $8.32 (+20.58%) |
Aug 7, 2026 7w ago | S-3 | $7.00 $7.76 | ▼ −10.87% | ▼ −11.78% | $8.32 (−18.86%) |
Aug 6, 2026 8w ago | 8-K | $7.49 $8.24 | ▲ +10.01% | ▲ +9.41% | $8.32 (+11.08%) |
Jul 18, 2026 10w ago | S-3 | $4.97 $7.15 | ▼ −43.86% | ▼ −39.74% | $8.32 (−67.40%) |
Jul 13, 2026 11w ago | 8-K | $6.12 $7.00 | ▼ −14.38% | ▼ −11.19% | $8.32 (−35.95%) |
May 13, 2026 20w ago | DEFA14A | $3.47 $3.39 | ▼ −2.31% | ▼ −1.69% | $8.32 (+139.77%) |
May 11, 2026 20w ago | 8-K | $3.26 $3.11 | ▼ −4.60% | ▼ −4.30% | $8.32 (+155.21%) |
Dec 4, 2025 43w ago | Court Ruling | $4.06 $3.22 | ▲ +20.69% | ▲ +21.18% | $8.32 (−104.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access